Function Health Ideal Patient Profile: Who Gets the Most From It?

What Function Health Actually Is

Function Health is a direct-to-consumer lab subscription that provides two annual blood draws covering roughly 100 biomarkers per panel. The service pairs results with an app-based dashboard that categorizes values as optimal, borderline, or out-of-range. Co-founder Dr. Mark Hyman, a functional medicine physician, has positioned the platform as a prevention tool grounded in longitudinal biomarker tracking.

The business model is straightforward: pay an annual fee, get your blood drawn at a partner lab, and receive an organized report. Function Health does not prescribe drugs. Any abnormal result requires independent follow-up with a licensed clinician.

What the Panel Covers

The approximately 100-biomarker panel includes lipid subfractions (apolipoprotein B, Lp(a), LDL-P), inflammatory markers (high-sensitivity CRP, homocysteine), metabolic markers (fasting insulin, HbA1c, HOMA-IR), thyroid function (TSH, free T3, free T4, reverse T3), sex hormones (total and free testosterone, estradiol, DHEA-S, SHBG), complete metabolic panel, CBC with differential, and several nutrient markers (25-OH vitamin D, ferritin, B12, magnesium).

Standard annual physicals covered by Medicare or commercial insurance typically include far fewer tests. A 2021 analysis published in JAMA Internal Medicine noted that routine preventive visits often miss metabolic and cardiovascular risk markers that extended panels capture [1].

What the Panel Does Not Cover

Function Health does not routinely include genetic sequencing, imaging (coronary artery calcium scoring, DEXA), continuous glucose monitoring, or stool-based microbiome analysis. For patients seeking a fully integrated longevity evaluation, these gaps matter. The USPSTF recommends coronary artery calcium scoring only in specific risk categories, but it adds clinical context that blood alone cannot provide [2].

Who Gains the Most: The Ideal Patient Profile

Not every adult benefits equally from 100-biomarker monitoring. The return on investment scales with baseline risk, health literacy, and the willingness to act on results.

Adults 35 to 65 With Emerging Metabolic Risk

Insulin resistance precedes type 2 diabetes by a decade or more in many patients. The CDC estimates that 96 million American adults, roughly 38% of the adult population, have prediabetes, and more than 80% are unaware of it [3]. A standard fasting glucose misses a substantial fraction of these cases; fasting insulin and HOMA-IR catch earlier dysfunction.

Function Health's panel includes both. An adult with a fasting glucose of 99 mg/dL, technically normal, may carry a HOMA-IR of 3.5 or higher, signaling meaningful insulin resistance. Catching that pattern at 38 rather than 52 creates a longer runway for lifestyle intervention.

People With a Family History of Cardiovascular Disease

Lipoprotein(a), or Lp(a), is a genetically determined cardiovascular risk marker that standard lipid panels do not measure. The European Atherosclerosis Society 2022 consensus statement recommended that every adult have Lp(a) measured at least once in a lifetime [4]. Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) is found in roughly 20% of the global population and roughly doubles the risk of atherosclerotic cardiovascular events independent of LDL cholesterol [4].

A 45-year-old with a father who died of a myocardial infarction at 58, normal LDL on a standard panel, but Lp(a) of 180 nmol/L has a very different risk profile than their lipid panel alone suggests. Function Health captures this. Most insurance-covered annual labs do not.

Thyroid Symptom Sufferers Dismissed by TSH-Only Screening

Standard thyroid screening in the United States is TSH alone. The American Thyroid Association acknowledges that TSH has limitations in detecting subclinical thyroid dysfunction and that free T3, free T4, and reverse T3 provide a more complete picture in symptomatic patients [5]. Patients who have been told their thyroid is "normal" based on a TSH of 3.2 mIU/L, but who carry fatigue, weight gain, and cold intolerance, may find that a free T3 at the lower end of range or an elevated reverse T3 gives their clinician more actionable data.

Function Health's inclusion of the full thyroid panel addresses a genuine gap in routine care.

High-Functioning Adults Optimizing Performance

Executives, athletes, and adults focused on healthspan often want longitudinal data on markers that standard care does not monitor annually: DHEA-S trajectory, ferritin trends, testosterone decline curves, and inflammatory marker drift. These are not trivial metrics. A 2019 study in The Journal of Clinical Endocrinology and Metabolism found that low DHEA-S was independently associated with all-cause mortality in men over 50, even after adjusting for testosterone [6].

Tracking these markers annually gives a data-literate adult a personal baseline against which future draws are compared, which is the core value proposition of the platform.

Who Function Health Is NOT Designed For

Patients Who Need Active Clinical Management

Function Health identifies abnormalities. It does not manage them. A patient with newly flagged hypothyroidism still needs a prescribing clinician. Someone whose apolipoprotein B comes back at 140 mg/dL still needs a physician to weigh statin initiation against the ACC/AHA pooled cohort equations [7]. The platform produces data; it does not produce treatment.

Adults who are already in active management for chronic conditions (type 2 diabetes, established cardiovascular disease, autoimmune thyroid disease) likely get more clinical value from working closely with their existing care team than from adding a parallel subscription panel.

Patients Without a Primary Care Physician

The USPSTF recommendation framework assumes that abnormal screening results feed into a clinical relationship [2]. Function Health's terms of service explicitly acknowledge that users should follow up abnormal results with a licensed provider. An adult with no primary care physician who receives 15 out-of-range values has a dashboard full of information and no immediate clinical infrastructure to act on it.

Budget-Constrained Adults With No Cardiovascular or Metabolic Risk Factors

For a 28-year-old non-smoker with a healthy BMI, no family history of cardiovascular disease or diabetes, normal energy levels, and no hormonal complaints, the $499 annual cost produces a high volume of data with a statistically low probability of actionable findings. The marginal clinical utility is lower in this cohort.

Is Function Health Legit? A Critical Assessment

The core concern about direct-to-consumer lab services is whether data-rich testing actually improves outcomes, or whether it generates anxiety and unnecessary follow-up without changing mortality curves.

The Evidence Base for Comprehensive Biomarker Screening

A 2023 systematic review in BMJ Open examining multiplex biomarker screening in asymptomatic adults found that extended panels improved detection of subclinical metabolic and cardiovascular disease, but that clinical benefit depended entirely on integration with guideline-based treatment [8]. Detection without treatment does not move outcomes.

Function Health's value is real when a user takes flagged results to a clinician and that clinician acts on them. The platform itself does not close the loop.

Regulatory and Lab Quality

Function Health processes samples through CLIA-certified laboratories. The Clinical Laboratory Improvement Amendments program, administered through CMS and the CDC, sets quality standards for all clinical laboratory testing in the United States [9]. CLIA certification is a meaningful floor, not a ceiling, but it establishes that the lab results are technically comparable to those from hospital-based or reference labs.

The platform is not FDA-approved as a diagnostic device. The labs it orders are FDA-cleared or CLIA-regulated assays, which is the standard for blood-based biomarker testing.

Clinician Credibility

Dr. Mark Hyman's functional medicine background attracts both committed advocates and legitimate critics. Functional medicine as a practice style sits in a contested space in evidence-based medicine. However, the specific biomarkers Function Health measures (Lp(a), apolipoprotein B, fasting insulin, homocysteine, hs-CRP) are not fringe or alternative markers. All five appear in peer-reviewed cardiovascular and metabolic disease literature and in major society guidelines.

The American College of Cardiology/American Heart Association 2019 guideline on primary cardiovascular prevention specifically identifies apolipoprotein B and Lp(a) as risk-enhancing factors that clinicians should consider when deciding on statin therapy [7].

Function Health vs. Alternatives

The following comparison covers the main competing models in the direct-to-consumer and concierge lab space.

Function Health vs. Labcorp OnDemand / Quest Direct

Labcorp OnDemand and Quest Direct allow consumers to purchase individual or bundled panels without a physician order. Per-test pricing means a comparable 100-biomarker package would cost significantly more than Function Health's $499 subscription if purchased a la carte. The tradeoff is flexibility: a consumer who wants only a lipid subfraction panel can buy exactly that without committing to an annual subscription.

Function Health's advantage is the curated, longitudinal dashboard. Its limitation is that you pay for the full panel whether or not every marker is relevant to you.

Function Health vs. Everlywell

Everlywell focuses on at-home finger-prick collection kits. The convenience is real for patients who cannot easily access a phlebotomy site. The clinical limitation is that fingerstick blood volumes restrict the number of assays that can run reliably. A 2020 letter in the Annals of Internal Medicine flagged the potential for higher coefficient-of-variation error rates in small-volume finger-prick samples compared to venipuncture for lipid markers [10].

Function Health uses standard venipuncture, which is the reference standard for the markers it runs.

Function Health vs. Concierge Medicine (e.g., One Medical, Parsley Health)

Concierge and hybrid-concierge models like Parsley Health offer comprehensive panels bundled with physician consultations and treatment authority. Parsley Health's annual membership (roughly $1,500 to $2,500 per year at current pricing) includes clinician-guided interpretation and, where appropriate, prescriptions. Function Health at $499 costs less but delivers only the data layer.

For patients who need both data and clinical management, a concierge model may produce better health outcomes despite the higher cost. For patients who already have a competent primary care or functional medicine physician and simply want richer lab data to bring to those visits, Function Health fills that specific gap efficiently.

Function Health vs. InsideTracker

InsideTracker offers tiered biomarker plans ranging from focused panels to comprehensive draws, with algorithm-driven recommendations for nutrition, supplements, and lifestyle. The platform is aimed primarily at athletic performance optimization. Its top-tier "Ultimate" panel is comparable in scope to Function Health's offering, at a similar price point.

The key difference is interpretation style. InsideTracker emphasizes performance-range optimization (targeting the top quartile of a reference range rather than simply avoiding out-of-range values). Function Health uses clinically derived reference ranges and flags values that cross guideline-defined thresholds.

Function Health and Lab-Driven Longevity: What the Science Supports

The longevity medicine field, sometimes called "precision preventive medicine," draws heavily on the concept that early detection of subclinical disease allows intervention before clinical events occur. The theoretical framework is well-supported. The practical evidence for subscription-model lab services specifically is thinner.

Where the Evidence Is Strong

Lp(a) screening is strongly evidence-backed. A Mendelian randomization study published in JAMA Cardiology (N=460,506) found that genetically elevated Lp(a) was causally associated with a 2-fold increase in coronary heart disease risk [11]. Identifying elevated Lp(a) before a first myocardial infarction creates an opportunity for more aggressive LDL lowering (since PCSK9 inhibitors modestly reduce Lp(a)) and aspirin or lifestyle counseling discussions with a cardiologist.

HbA1c and fasting insulin tracking is also evidence-supported. The Diabetes Prevention Program (DPP, N=3,234) demonstrated that intensive lifestyle intervention in adults with impaired glucose tolerance reduced diabetes incidence by 58% over 2.8 years compared to placebo [12]. Identifying impaired glucose tolerance earlier (which a combined HbA1c plus fasting insulin measurement makes more likely than HbA1c alone) extends the window for intervention.

Where the Evidence Is Weaker

Reverse T3 measurement, included in Function Health's thyroid panel, has limited clinical guideline support. The American Thyroid Association does not endorse reverse T3 as a routine screening marker [5]. Some functional medicine practitioners treat elevated reverse T3 as evidence of "tissue-level hypothyroidism," but this interpretation is not supported by randomized trial data. Including reverse T3 in a panel creates a risk of over-interpretation and unnecessary thyroid hormone supplementation.

Homocysteine testing occupies a similar gray zone. Elevated homocysteine is associated with cardiovascular risk epidemiologically, but the VITATOPS trial (N=8,164) found that B-vitamin supplementation to lower homocysteine did not significantly reduce major vascular events [13]. The marker may identify risk without a clearly effective intervention.

This is the practical limitation of comprehensive panels: not every out-of-range value has an evidence-based treatment attached to it.

Integrating Function Health Data Into Clinical Care

The single most important step a Function Health user can take is scheduling a follow-up visit with a primary care physician or specialist after receiving results. Flagged values that go unaddressed do not improve health outcomes. A 2022 review in Annals of Internal Medicine examining direct-to-consumer genetic and lab testing found that consumer-ordered tests resulted in actionable clinical changes in only 26% of cases where findings were clinically significant, largely because users lacked a clinical relationship to bring results into [14].

Bring the full Function Health PDF report to the appointment, not just the app screenshot. Ask specifically about any value flagged as out-of-range and request a clinical interpretation in the context of your personal risk history, not solely based on population reference ranges.

For HealthRX members using GLP-1 therapy, testosterone replacement, or other hormonal treatments, Function Health's inclusion of fasting insulin, lipid subfractions, testosterone, and SHBG makes it a reasonable supplemental monitoring tool between standard quarterly or biannual labs. It does not replace medication-specific monitoring (for example, hematocrit monitoring on testosterone therapy per Endocrine Society guidelines [15]).

Cost Analysis: Is Function Health Worth $499 Per Year?

At $499 per year for two draws, Function Health works out to roughly $250 per comprehensive panel. Purchasing a comparable panel a la carte through Labcorp or Quest (without a physician order discount) would cost substantially more: apolipoprotein B alone runs $30 to $80 depending on the lab, Lp(a) runs $25 to $90, and fasting insulin runs $20 to $60. A 100-biomarker a-la-carte build easily reaches $800 to $1,500 at retail pricing.

From a pure per-biomarker cost standpoint, Function Health is competitively priced for users who intend to track the full panel.

The question is whether you will act on the results. If a flagged apolipoprotein B triggers a cardiology referral that leads to rosuvastatin 10 mg daily, the $499 subscription paid for itself many times over. If the results sit in an app and no clinical action follows, the value proposition collapses.